Search is Powered by Google
Follow us on:
Follow our health news on Twitter
Follow Our News on Facebook
Personalization
login | register
Muscular Dystrophy / ALS News

Maas Biolab SBIR Enters Phase 2 For Cyclosporin ALS Treatment

Main Category: Muscular Dystrophy / ALS
Also Included In: Clinical Trials / Drug Trials
Article Date: 05 Dec 2008 - 1:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:5 stars

5 (2 votes)

Health Professional:not yet rated

Article Opinions: 0 posts

Maas Biolab has advanced to Phase 2 of its Small Business Innovation Research (SBIR) grant "Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis (ALS)." Jenny Karlsson, Ph.D., is Maas Director of Preclinical Development and Principal Investigator of the $2.1 million three-year grant from the National Institute of Neurological Disorders and Stroke (NINDS). After successful completion of Phase 1 established initial Mitogard® stability and drug safety for the new intrathecal route for cyclosporin, the amount of $894,000 for year two was released by the National Institutes of Health (NIH).

"The first year's results show Mitogard® intrathecal safety in the therapeutic range, and we look forward with excitement to the second year's more in-depth toxicology testing," says Dr. Karlsson.

Phase 2 will complete the preclinical stability, toxicology and pharmacokinetics over the next two years to enable the first human clinical trials for Maas Biolab's Mitogard® intrathecal cyclosporin formula. The Veterans Administration Clinical Research Pharmacy Coordinating Center, Albuquerque, N.M., performs stability testing. Northern Biomedical Research, Muskegon, Mich., conducts the intrathecal testing.

Thirty thousand Americans have ALS. Progressive loss of motor neurons causes paralysis and death within three years. Injections of cyclosporin into the CSF bypass the blood brain barrier and extend survival in the SOD1 G93A transgenic ALS mouse at low non-immunosuppressive doses.

Maas Biolab, LLC

Maas Biolab is a private pharmaceutical company in Albuquerque, N.M., USA developing Mitogard®, the only cyclosporin formula designed for CSF delivery, to treat ALS. Maas Biolab holds FDA Orphan Drug Designation for cyclosporin to treat ALS and world patents for cyclosporin neuroprotection against chronic neurological diseases. http://www.maasbiolab.com

NeuroVive Pharmaceutical AB is a partner producing NeuroSTAT®, a patented intravenous cyclosporin formula to treat traumatic brain injury. http://www.neurovive.com

The project described is supported by Grant Number U44NS059084 from the NINDS. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Neurological Disorders and Stroke or the National Institutes of Health.

NeuroVive Pharmaceutical




Personalized Homepage Weekly Newsletters Daily News Alerts
Hemophilia Opioid Induced Constipation Pneumococcal Disease ADHD Anxiety Asthma Atrial Fibrillation Autism Cancer Diabetes Lung Cancer Lupus Medicare / Medicaid Obesity and BMI Pancreatic Cancer Stem Cells All 'What Is...' Articles

Ophthalmology Urology
About Us News Licensing Free Website Feeds Free Tools & Content Tell a Friend Accessibility Help / FAQ Article Submission Links Contact Us

add medical news today to your facebook
medical news gadget

Please fill in our survey

Swine Flu Image

Swine Flu Updates

- Latest Swine Flu News
- What is Swine Flu?
- Map Of H1N1 Outbreaks
- Swine Flu - Top 20 FAQ
- Daily Email News Alerts
Stick with Medical News Today for the latest news updates on swine flu.


These are the most read articles from this news category for the last 6 months:
Top Article Star
What Is Ataxia? What Causes Ataxia?
31 Aug 2009
Ataxia is a lack of muscle coordination which may affect speech, eye movements, the ability to swallow, walking, picking up objects and other voluntary movements. A person with persistent ataxia may have damage in the part...


Manicure & Pedicure Hazards
Manicure & Pedicure Hazards

Getting a manicure or a pedicure can put you at risk for developing a skin allergy or infection. Taking some common sense precautions can help you avoid those risks.

more videos are available in our health videos section.